Litigation Details for Orion Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2025)

Orion Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2025)

Docket		Date Filed	2025-07-03
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Patents	10,010,530; 10,383,853; 10,835,515; 11,168,058
Link to Docket	External link to docket

Details for Orion Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-07-03				External link to document

Litigation summary and analysis for: Orion Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2025)

Last updated: May 8, 2026

Orion Corporation v. Alembic Pharmaceuticals Limited (1:25-cv-00825): Litigation Summary and Patent-Strategy Analysis

Orion Corporation has filed a patent infringement action against Alembic Pharmaceuticals Limited in the U.S. District Court for the District of Delaware under case number 1:25-cv-00825. The filing is a Hatch-Waxman-style dispute in the FDA ANDA pathway (per the docket’s structure and typical pleading format for this case type), where Orion’s asserted U.S. patents target an Orion-marketed product and Alembic seeks approval to market a generic version.

Bottom line: the litigation will likely center on (1) product-to-patent claim mapping, (2) ANDA label and Paragraph IV statutory defenses, (3) entitlement to a failure-to-state/invalidity attack (depending on Orion’s pleading), and (4) infringement timing through the “artificial infringement” framework under 35 U.S.C. § 271(e)(2).

---

What is the case and where is it filed?

• Caption: Orion Corporation v. Alembic Pharmaceuticals Limited
• Court: U.S. District Court, District of Delaware
• Case number: 1:25-cv-00825
• Filing year: 2025

This is a federal patent action targeting Alembic’s FDA submission and the anticipated launch of a generic drug product.

---

What claims and legal hooks are typically at issue in this posture?

In Delaware ANDA patent litigations with a brand sponsor plaintiff, the operative allegations almost always fall into four buckets:

1. Infringement under 35 U.S.C. § 271(e)(2)
   The plaintiff alleges that the ANDA submission, including the proposed manufacturing and proposed labeling, infringes asserted claims of one or more U.S. patents.

2. Paragraph IV invalidity and non-infringement defenses
   The generic defendant typically contests one or more elements of the infringement theory and asserts invalidity (anticipation, obviousness, indefiniteness, lack of enablement, or written description).

3. Patent scope and claim construction
   The parties fight claim meaning early. Claim construction usually drives whether the case is narrowed for summary judgment, stipulations, or trial.

4. 30-month stay and launch timing
   Depending on the timing of the suit and the FDA regulatory posture, the plaintiff may seek to keep FDA from approving the ANDA until litigation milestones are reached.

Because the litigation is docketed in 2025 and framed under a Delaware patent track, the procedural schedule will likely align with standard ANDA timelines: Rule 16 scheduling, early claim construction, then dispositive motions.

---

What does a 2025 Orion v. Alembic complaint usually require Orion to prove?

Orion must establish, for each asserted patent claim:

• A claim construction that reads on the proposed generic product (composition and/or method claim coverage).
• Infringement through the ANDA submission under the § 271(e)(2) “submission-based” standard.
• For means-plus-function or functional claim terms, adequate structure/indefiniteness positions must be resolved through claim construction briefing.

The “hard part” for brand plaintiffs in ANDA cases is often claim mapping to the generic’s proposed dosage form, route, dose regimen, and any composition or method limitations tied to the clinical and commercial product attributes described in the Orange Book.

---

How will claim construction likely drive the infringement outcome?

Patent cases of this type usually hinge on a small number of claim terms rather than the entire claim set. Typical high-leverage term categories include:

• Chemical or formulation limitations (e.g., defined active moiety, salt/hydrate form, polymorph-specific descriptors).
• Process/method limitations (e.g., steps that define preparation, formulation, or use conditions).
• Functional limitations (requiring a corresponding structure or prior art support).
• Priority-bound term scope that affects anticipation/obviousness analysis.

Claim construction is also where the court can decide whether a plaintiff can rely on a broad claim reading or must live with a narrower interpretation.

---

What defenses will Alembic likely pursue based on the typical ANDA pattern?

Alembic’s litigation posture will usually include some mix of:

• Non-infringement arguments

  • The proposed generic formulation or method does not meet one or more claim limitations.
  • The ANDA label or instructions fail to satisfy any “use” claim limitations.

• Invalidity attacks

  • Anticipation: a single prior art reference discloses the claimed subject matter.
  • Obviousness: combinations of references render the claims obvious.
  • Indefiniteness: claim terms fail § 112 clarity.
  • Written description / enablement: specification does not support full claim scope.

• Procedural defenses

  • Motions challenging pleading sufficiency or standing are less common in fully formed ANDA infringement cases but can appear early.

The court will typically separate claim construction from validity and infringement for dispositive motions unless the case is unusually compressed.

---

What is the likely patent strategy on Orion’s side?

Brand plaintiffs in this posture generally aim to:

• Assert the highest-likelihood patents first (those most tied to a core formulation or method element rather than minor dependent claim variations).
• Keep infringement arguments product-specific to avoid an overly abstract theory that becomes vulnerable to invalidity.
• Use expert-driven mapping: a single “representative” claim set often anchors the narrative and reduces the cost of responding to multiple invalidity theories.

If Orion asserts multiple patents, it typically does so to create a hedge against partial invalidity or narrow claim construction.

---

What is the likely generic strategy on Alembic’s side?

Generic defendants usually pursue:

• Narrow claim construction to remove coverage.
• Design-around through ANDA label and formulation constraints (where the proposed product can be adjusted or re-parameterized).
• Prior art focus on the most vulnerable claim elements, not every limitation.

If the generic can show a gap on a single key limitation, it often avoids full invalidity trials.

---

What procedural milestones should be expected next?

While the exact dates depend on the court’s scheduling order, ANDA patent cases in Delaware usually proceed in a predictable sequence:

1. Rule 16 scheduling conference and entry of a scheduling order
2. Patent disclosures and infringement/invalidity contentions under the local rules
3. Claim construction process (Markman hearing timing set by the schedule)
4. Dispositive motions (often summary judgment on infringement or invalidity after claim construction)
5. Pretrial submissions and trial date set if cases survive dispositive motions

The fastest path to resolution is usually early non-infringement on a claim term that collapses the case, or a strong invalidity record once claim scope is set.

---

What business implications matter for an investor or R&D sponsor?

• For Orion: the value driver is whether the asserted claims read cleanly on Alembic’s proposed product and whether claim construction preserves the claim scope against invalidity. If the case narrows early, Orion’s settlement leverage rises.
• For Alembic: the value driver is whether a narrow claim construction and prior art can eliminate infringement without forcing a full trial. If key claim terms fail to map to the proposed product, Alembic’s risk reduces quickly.
• For generic competition timeline: the litigation’s pace affects FDA approval and potential launch date. Any settlement that includes launch-date restrictions can shift market entry economics.

---

Key Takeaways

• Case: Orion Corporation v. Alembic Pharmaceuticals Limited, 1:25-cv-00825, filed in the District of Delaware in 2025.
• Core legal framework: infringement is likely alleged under 35 U.S.C. § 271(e)(2) tied to an FDA ANDA submission.
• Main fight: claim construction and product-to-claim mapping, followed by invalidity or non-infringement.
• Business impact: the quickest path to resolution is usually a narrow claim construction that eliminates one or more essential infringement limitations.

---

FAQs

1) Is this an ANDA patent case?

Yes. The case posture aligns with Hatch-Waxman ANDA patent infringement litigation, where the brand alleges infringement based on the generic’s ANDA submission under 35 U.S.C. § 271(e)(2).

2) What usually determines infringement in these cases?

Whether the proposed generic product and/or proposed labeling meet each asserted claim limitation after the court construes key claim terms.

3) What defenses typically decide these cases early?

Strong non-infringement on a single key limitation after claim construction, or an invalidity theory that targets core claim elements.

4) Does the court consider FDA approval directly?

The court does not “approve” drugs, but the litigation’s outcome affects FDA’s ability to move forward and the generic launch timetable.

5) What is the most important next procedural event?

Claim construction, because it sets the scope that controls both infringement mapping and invalidity analysis.

---

References

[1] United States Code, Title 35, Section 271(e)(2).